Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1980 Feb;39(2):416–425.

Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice.

R I Fisher, G L Mandell, F Bostick, M G McMenamin, T Anderson
PMCID: PMC1538078  PMID: 6446427

Abstract

Chlorozotocin is a new nitrosourea anti-tumour drug that does not produce bone marrow suppression at therapeutic doses in mice. CDF1 mice which were injected i.p. with a dose lethal to 10% of animals within 60 days (LD10), 20 mg/kg, developed a 50% reduction in circulating peripheral blood lymphocytes without a decrease in circulating granulocytes by day 3. Spleen weight also decreased markedly. The percentage of spleen B and T cells, determined by immunofluorescence with goat anti-mouse IgG and rabbit anti-mouse brain antisera, did not differ in control and chlorozotocin-treated mice. However, the ability of residual spleen cells to proliferate in response to phytohaemagglutinin, concanavalin A, pokeweed mitogen, and allogeneic cells was significantly suppressed although the lipopolysaccharide response was not reduced. The ability of the mice to respond to a primary immunization with sheep red blood cells was not significantly impaired. Therefore, chlorozotocin has a cytotoxic effect on both B and T cells but selectively inhibits the proliferative capacity of T cells. B cell proliferation and B cell function as measured in a primary antibody response were not reduced. These studies suggest chlorozotocin may be useful as an immunosuppressive drug as well as an anti-tumour agent.

Full text

PDF
416

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T., McMenamin M. G., Schein P. S. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. Cancer Res. 1975 Mar;35(3):761–765. [PubMed] [Google Scholar]
  2. Carter S. K. An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3. 1973 May;4(3):35–46. [PubMed] [Google Scholar]
  3. De Vita V. T., Carbone P. P., Owens A. H., Jr, Gold G. L., Krant M. J., Edmonson J. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res. 1965 Dec;25(11):1876–1881. [PubMed] [Google Scholar]
  4. Gery I., Krüger J., Spiesel S. Z. Stimulation of B-lymphocytes by endotoxin. Reactions of thymus-deprived mice and karyotypic analysis of dividing cells in mice bearing T 6 T 6 thymus grafts. J Immunol. 1972 Apr;108(4):1088–1091. [PubMed] [Google Scholar]
  5. Hansen H. H., Selawry O. S., Muggia F. M., Walker M. D. Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res. 1971 Mar;31(3):223–227. [PubMed] [Google Scholar]
  6. Harrison S. D., Jr, Denine E. P., Peckham J. C. Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF mice. Cancer Treat Rep. 1978 Apr;62(4):533–545. [PubMed] [Google Scholar]
  7. Hodes R. J., Handwerger B. S., Terry W. D. Synergy between subpopulations of mouse spleen cells in the in vitro generation of cell-mediated cytotoxicity: evidence for the involvement of a non-T cell. J Exp Med. 1974 Dec 1;140(6):1646–1659. doi: 10.1084/jem.140.6.1646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Janossy G., Greaves M. F. Lymphocyte activation. II. discriminating stimulation of lymphocyte subpopulations by phytomitogens and heterologous antilymphocyte sera. Clin Exp Immunol. 1972 Mar;10(3):525–536. [PMC free article] [PubMed] [Google Scholar]
  9. Kaplan S. R., Calabresi P. Drug therapy. Immunosuppressive agents. I. N Engl J Med. 1973 Nov 1;289(18):952–955. doi: 10.1056/NEJM197311012891806. [DOI] [PubMed] [Google Scholar]
  10. Moertel C. G. Therapy of advanced gastrointestinal cancer with the nitrosoureas. Cancer Chemother Rep 3. 1973 May;4(3):27–34. [PubMed] [Google Scholar]
  11. Otterness I. G., Chang Y. H. Comparative study of cyclophosphamide, 6-mercaptopurine, azathiopurine and methotrexate. Relative effects on the humoral and the cellular immune response in the mouse. Clin Exp Immunol. 1976 Nov;26(2):346–354. [PMC free article] [PubMed] [Google Scholar]
  12. Schein P. S., McMenamin M. G., Anderson T. 3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity. Cancer Res. 1973 Sep;33(9):2005–2009. [PubMed] [Google Scholar]
  13. Schein P. S., O'Connell M. J., Blom J., Hubbard S., Magrath I. T., Bergevin P., Wiernik P. H., Ziegler J. L., DeVita V. T. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer. 1974 Oct;34(4):993–1000. doi: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  14. Shortman K., Byrd W. J., Cerottini J. C., Brunner K. T. Characterisation and separation of mouse lymphocyte subpopulations responding to phytohemagglutinin and pokeweed mitogens. Cell Immunol. 1973 Jan;6(1):25–40. doi: 10.1016/0008-8749(73)90003-8. [DOI] [PubMed] [Google Scholar]
  15. Thorpe P. E., Knight S. C. Microplate culture of mouse lymph node cells. I. Quantitation of responses to allogeneic lymphocytes endotoxin and phytomitogens. J Immunol Methods. 1974 Oct;5(4):387–404. doi: 10.1016/0022-1759(74)90022-2. [DOI] [PubMed] [Google Scholar]
  16. Tobey R. A., Oka M. S., Crissman H. A. Differential effects of two chemotherapeutic agents, streptozotocin and chlorozotocin, on the mammalian cell cycle. Eur J Cancer. 1975 Jun;11(6):433–441. doi: 10.1016/0014-2964(75)90075-4. [DOI] [PubMed] [Google Scholar]
  17. Walker M. D. Nitrosoureas in central nervous system tumors. Cancer Chemother Rep 3. 1973 May;4(3):21–26. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES